We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
-19.99%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$887M
AUM Growth
+$16.2M
Cap. Flow
-$2.28M
Cap. Flow %
-0.26%
Top 10 Hldgs %
50.79%
Holding
136
New
23
Increased
31
Reduced
31
Closed
36

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$34.3M
2
AZN icon
AstraZeneca
AZN
+$20.1M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$14.8M
4
VTRS icon
Viatris
VTRS
+$11.4M
5
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$10.3M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$44.9M
2
MRK icon
Merck
MRK
+$22.8M
3
GSK icon
GSK
GSK
+$21.9M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.53M
5
V icon
Visa
V
+$6.06M

Sector Composition

Rank Sector Weight
1 Healthcare 61.74%
2 Miscellaneous 22.61%
3 Technology 12.21%
4 Industrials 2.92%
5 Consumer Discretionary 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRMR icon
76
Larimar Therapeutics
LRMR
$402M
$1.88M 0.21%
31,667
-4,166
-12% -$411K
ALNA
77
DELISTED
Allena Pharmaceuticals
ALNA
$1.88M 0.21%
345,199
+50,000
+17% +$431K
PVLA
78
Palvella Therapeutics
PVLA
$2.21B
$1.86M 0.21%
8,750
-2,559
-23% -$794K
ARRY
79
DELISTED
Array Biopharma Inc
ARRY
$1.78M 0.2%
125,000
-270,000
-68% -$4.1M
MTEM
80
DELISTED
Molecular Templates, Inc.
MTEM
$1.62M 0.18%
26,667
– –
APLS
81
DELISTED
Apellis Pharmaceuticals
APLS
$1.54M 0.17%
117,000
-95,470
-45% -$1.46M
UROV
82
DELISTED
Urovant Sciences Ltd.
UROV
$1.41M 0.16%
214,030
+50,000
+30% +$455K
DOVA
83
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$1.4M 0.16%
185,000
+65,000
+54% +$1.05M
MLNT
84
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$1.28M 0.14%
323,373
– –
CLSD
85
DELISTED
Clearside Biomedical
CLSD
$1.27M 0.14%
79,008
+2,029
+3% +$95.2K
ACGN
86
DELISTED
Aceragen Inc
ACGN
$1.23M 0.14%
26,236
– –
CRVS icon
87
Corvus Pharmaceuticals
CRVS
$1.07B
$1.18M 0.13%
321,430
– –
SVRA icon
88
Savara
SVRA
$1.11B
$833K 0.09%
110,000
-99,596
-48% -$896K
PHXM
89
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$796K 0.09%
12,000
– –
VRCA icon
90
Verrica Pharmaceuticals
VRCA
$80.6M
$791K 0.09%
9,700
-2,000
-17% -$243K
MGTX icon
91
MeiraGTx Holdings
MGTX
$1.25B
$686K 0.08%
+71,159
New +$898K
FSTX
92
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$530K 0.06%
+12,754
New +$574K
KZR
93
DELISTED
Kezar Life Sciences
KZR
$472K 0.05%
2,000
-19,200
-91% -$4.69M
SRRA
94
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$341K 0.04%
6,463
-19,106
-75% -$1.22M
CNST
95
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$281K 0.03%
+70,162
New +$423K
CUE icon
96
Cue Biopharma
CUE
$267M
$235K 0.03%
1,667
+1,000
+150% +$181K
ADVM
97
DELISTED
Adverum Biotechnologies
ADVM
$200K 0.02%
6,336
-1,164
-16% -$47.3K
BNTC icon
98
Benitec Biopharma
BNTC
$393M
$180K 0.02%
471
– –
CLRB icon
99
Cellectar Biosciences
CLRB
$22.6M
$136K 0.02%
292
– –
AAP icon
100
Advance Auto Parts
AAP
$2.54B
– –
-5,336
Closed -$898K
2 3
4
5 6

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q4 2018 Portfolio in Review

As of Q4 2018, Sphera Funds Management held 136 positions worth $887M, up 1.9% from $871M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Sphera Funds Management's Q4 2018 filing shows 23 new, 31 increased, 31 reduced and 36 closed positions. Its largest new stake was Celgene Corp: 465,000 shares worth $29.8M. The largest sale was Johnson & Johnson, an estimated $44.9M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 77% a quarter earlier, followed by Miscellaneous and Technology.

  • Sphera Funds Management's largest Q4 2018 buy was Celgene Corp: 465,000 shares worth $29.8M.
  • Sphera Funds Management added most to Viatris in Q4 2018, an estimated $11.4M increase.
  • Sphera Funds Management's biggest Q4 2018 reduction was Merck, cutting an estimated $22.8M.
  • Sphera Funds Management fully exited Johnson & Johnson in Q4 2018, selling an estimated $44.9M.
  • Sphera Funds Management's ten largest holdings make up 51% of its $887M portfolio in Q4 2018.
  • Sphera Funds Management opened 23 new positions and closed 36 in Q4 2018.
  • Sphera Funds Management's portfolio value rose 1.9% quarter-over-quarter to $887M.

Based on Sphera Funds Management's 13F filing for Q4 2018, filed 14 Feb 2019.